Seppo W. Langer

Medicine & Life Sciences

1. 64Cu-DOTATATE 100%
2. Neuroendocrine Carcinoma 98%
3. Neuroendocrine Tumors 92%
4. Lung Neoplasms 74%
5. Ga(III)-DOTATOC 52%
6. Rehabilitation 44%
7. Small Cell Lung Carcinoma 37%
8. Exercise 35%
9. Drug Therapy 33%
10. Fluorodeoxyglucose F18 30%
11. Edotreotide 29%
12. somatostatin receptor 2 27%
13. Neoplasms 26%
14. Survival 25%
15. Carcinoid Tumor 24%
16. Positron Emission Tomography Computed Tomography 24%
17. Ganglioneuroblastoma 23%
18. Non-Small Cell Lung Carcinoma 22%
19. Multiple Hamartoma Syndrome 21%
20. Topotecan 20%
21. Dexrazoxane 20%
22. Therapeutics 19%
23. Prospective Studies 19%
24. Octreotide 19%
25. Progression-Free Survival 18%
26. Type II DNA Topoisomerase 18%
27. Positron-Emission Tomography 18%
28. Pancreatic Carcinoma 17%
29. Anthracyclines 16%
30. Feasibility Studies 16%
31. Gastrointestinal Tract 15%
32. Precision Medicine 15%